Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROZAC vs CELEXA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder with or without agoraphobia,Premenstrual dysphoric disorder,Bipolar depression (in combination with olanzapine)
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
Fluoxetine: 4-6 days; norfluoxetine: 4-16 days; extensive accumulation with chronic dosing, steady-state in 4-5 weeks
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Hepatic via CYP2D6, CYP2C9, CYP2C19, and CYP3A4; active metabolite norfluoxetine.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Renal: ~80% (primarily as metabolites, <10% unchanged); fecal: ~15%
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
~94.5% bound to albumin and alpha-1-acid glycoprotein
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
12-42 L/kg; extensive tissue binding, particularly in lungs and brain
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Oral: 60-80% due to first-pass metabolism; not administered parenterally
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
GFR 10-50 m L/min: administer 50% of usual dose; GFR <10 m L/min: administer 50% of usual dose or use alternative; not removed by hemodialysis.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
Child-Pugh Class A: no dose adjustment needed; Child-Pugh Class B: reduce dose by 50% or use alternative; Child-Pugh Class C: contraindicated or use alternative with caution.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Children 7-17 years: 10-20 mg orally once daily, initially; may increase to 20-40 mg once daily after ≥1 week; maximum 40 mg once daily.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Consider starting dose of 10 mg orally once daily; may increase slowly to 20 mg once daily; maximum 40 mg once daily; monitor for hyponatremia and QT prolongation.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality in pediatric patients,Activation of mania/hypomania,QT interval prolongation,Serotonin syndrome,Discontinuation syndrome,Bleeding risk (with NSAIDs/aspirin)
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Hypersensitivity to fluoxetine,Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide or thioridazine
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
Avoid grapefruit juice as it inhibits CYP3A4 and may increase fluoxetine levels. Alcohol may potentiate CNS depression; advise minimal or no alcohol use. No other significant food interactions.
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
First trimester: Studies suggest a small increased risk of cardiovascular malformations, particularly ventricular septal defects, with relative risk approximately 1.5-1.7. Third trimester: Exposure is associated with risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (including irritability, respiratory distress, feeding difficulty). Second trimester: No specific major risks identified beyond general population baseline.
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk. Milk-to-plasma ratio for fluoxetine is approximately 0.29. Infant serum levels can reach up to 10% of maternal therapeutic levels, with norfluoxetine accumulating. Adverse effects reported include irritability, poor feeding, and colic. American Academy of Pediatrics considers fluoxetine as a drug with 'potentially significant' effects; caution is advised, and breastfeeding should be weighed against maternal need.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
Pregnancy can decrease fluoxetine levels due to increased volume of distribution and hepatic metabolism; dose may need to be increased (20-40% on average) in third trimester, with tapering postpartum to pre-pregnancy dose to avoid toxicity. Therapeutic drug monitoring is recommended to maintain efficacy. No specific dose adjustment is standardized; individualization based on clinical response and serum levels is required.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
Commonly used in bulimia nervosa (60 mg/day) and premenstrual dysphoric disorder (20 mg/day continuously or 20 mg/day only during luteal phase). Requires 4-6 weeks for full therapeutic effect. Abrupt discontinuation may cause withdrawal symptoms; taper over 2-4 weeks. Risk of serotonin syndrome when combined with MAOIs, other serotonergic drugs, or linezolid. Lower starting dose (10 mg) in hepatic impairment or elderly. Suicidality warning especially in children, adolescents, and young adults.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
Take exactly as prescribed, usually once daily in the morning to minimize insomnia.,It may take 4-6 weeks to feel full benefit; do not stop abruptly.,Do not take with MAOIs or within 14 days of stopping MAOIs.,Report any suicidal thoughts, especially during the first few weeks.,Avoid alcohol and grapefruit juice as they may increase side effects.,If you miss a dose, skip it; do not double the next dose.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROZAC vs CELEXA, answered by our medical review team.
PROZAC is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.. CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROZAC and CELEXA depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROZAC is: 20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.. The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROZAC and CELEXA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROZAC is classified as Category C. First trimester: Studies suggest a small increased risk of cardiovascular malformations, particularly ventricular septal defects, with relative risk approximately 1.5-1.7. Third tr. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.